Cover Image

Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor

We have investigated the effects of a potent lipid-lowering therapy on the activity of platelets as measured ex vivo by the surface activation markers CD62 (PADGEM, P-selectin, GMP 140) and CD63 (GP53) in a double-blind, randomized, placebo-controlled study. Treatment with the HMG-CoA-reductase inhi...

Full description

Saved in:
Bibliographic Details
Main Authors: Huhle, Günter (Author) , Abletshauser, C. (Author) , Mayer, Norman (Author) , Weidinger, G (Author) , Harenberg, Job (Author) , Heene, Dieter L. (Author)
Format: Article (Journal)
Language:English
Published: 20 September 1999
In: Thrombosis research
Year: 1999, Volume: 95, Issue: 5, Pages: 229-234
ISSN:1879-2472
DOI:10.1016/S0049-3848(99)00037-7
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/S0049-3848(99)00037-7
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0049384899000377
Get full text
Author Notes:G. Huhle, C. Abletshauser, N. Mayer, G. Weidinger, J. Harenberg, D.L. Heene
Description
Summary:We have investigated the effects of a potent lipid-lowering therapy on the activity of platelets as measured ex vivo by the surface activation markers CD62 (PADGEM, P-selectin, GMP 140) and CD63 (GP53) in a double-blind, randomized, placebo-controlled study. Treatment with the HMG-CoA-reductase inhibitor fluvastatin (40 mg) significantly reduced the serum low density lipoprotein cholesterol concentration by 30% (p<0.01) and total cholesterol by 25% (p<0.01). The platelet membrane activation markers CD62 (PADGEM, P-selectin, GMP140) and 63 (GP53) significantly decreased by 22 and 13% (in terms of the relative fluorescence intensity) under the treatment with fluvastatin (p<0.05), respectively. The cholesterol-lowering effect is accompanied by a significant reduction of the platelet membrane activation markers CD62 and CD63 reflecting a reduced platelet activity that may contribute to the vasoprotective profile of fluvasatin.
Item Description:Gesehen am 05.05.2022
Physical Description:Online Resource
ISSN:1879-2472
DOI:10.1016/S0049-3848(99)00037-7

Similar Items